{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:20:23Z","timestamp":1777648823166,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vaccine.2024.05.017","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:06:03Z","timestamp":1716005163000},"page":"4056-4065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-8412","authenticated-orcid":false,"given":"Isabel","family":"Griffin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isha","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terese","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0479-0164","authenticated-orcid":false,"given":"Lalita","family":"Priyamvada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7188-8674","authenticated-orcid":false,"given":"William C.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Noiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-1433","authenticated-orcid":false,"given":"Michelle A.","family":"Waltenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1085-9903","authenticated-orcid":false,"given":"Will","family":"Still","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9244-7250","authenticated-orcid":false,"given":"Leah","family":"Lujan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Beverley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Willut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Shelus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina L.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0354-7437","authenticated-orcid":false,"given":"Michael B.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayampalli S.","family":"Satheshkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.05.017_b0005","doi-asserted-by":"crossref","unstructured":"Vaughan A, Aarons E, Astbury J, et al. Two cases of monkeypox imported to the United Kingdom, September 2018. Euro Surveill 2018; 23(38).","DOI":"10.2807\/1560-7917.ES.2018.23.38.1800509"},{"issue":"5","key":"10.1016\/j.vaccine.2024.05.017_b0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3201\/eid2805.220292","article-title":"Imported Monkeypox from International Traveler, Maryland, USA, 2021","volume":"28","author":"Costello","year":"2022","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2024.05.017_b0015","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3201\/eid2505.190076","article-title":"Diagnosis of imported Monkeypox, Israel, 2018","volume":"25","author":"Erez","year":"2019","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2024.05.017_b0020","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3201\/eid2608.191387","article-title":"Imported Monkeypox, Singapore","volume":"26","author":"Yong","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.017_b0025","doi-asserted-by":"crossref","unstructured":"Hobson G, Adamson J, Adler H, et al. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill 2021; 26(32).","DOI":"10.2807\/1560-7917.ES.2021.26.32.2100745"},{"issue":"4","key":"10.1016\/j.vaccine.2024.05.017_b0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMoa032299","article-title":"The detection of monkeypox in humans in the Western Hemisphere","volume":"350","author":"Reed","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2024.05.017_b0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.15585\/mmwr.mm7123e1","article-title":"Monkeypox outbreak - Nine States, May 2022","volume":"71","author":"Minhaj","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2024.05.017_b0040","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S1473-3099(22)00574-6","article-title":"Prevention of monkeypox with vaccines: a rapid review","volume":"22","author":"Poland","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2024.05.017_b0045","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1473-3099(19)30294-4","article-title":"Outbreak of human monkeypox in Nigeria in 2017\u201318: a clinical and epidemiological report","volume":"19","author":"Yinka-Ogunleye","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"10.1016\/j.vaccine.2024.05.017_b0050","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm7122e1","article-title":"Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.05.017_b0055","unstructured":"U.S. Food and Drug Administration. Monkeypox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply. <https:\/\/www.fda.gov\/news-events\/press-announcements\/monkeypox-update-fda-authorizes-emergency-use-jynneos-vaccine-increase-vaccine-supply> [accessed December 1]."},{"issue":"39","key":"10.1016\/j.vaccine.2024.05.017_b0060","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2015.06.075","article-title":"Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na\u00efve subjects","volume":"33","author":"Frey","year":"2015","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2024.05.017_b0065","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.15585\/mmwr.mm7145a4","article-title":"Epidemiologic features of the monkeypox outbreak and the public health response - United States, May 17-October 6, 2022","volume":"71","author":"Kava","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.05.017_b0070","unstructured":"Centers for Disease Control and Prevention. Monkeypox: Vaccination. <https:\/\/www.cdc.gov\/poxvirus\/monkeypox\/interim-considerations\/overview.html> [accessed December 1]."},{"key":"10.1016\/j.vaccine.2024.05.017_b0075","unstructured":"Centers for Disease Control and Prevention. JYNNEOS Vaccine. <https:\/\/www.cdc.gov\/poxvirus\/mpox\/interim-considerations\/jynneos-vaccine.html> [accessed January 11]."},{"issue":"50","key":"10.1016\/j.vaccine.2024.05.017_b0080","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1016\/j.vaccine.2022.10.078","article-title":"Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo","volume":"40","author":"Priyamvada","year":"2022","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2024.05.017_b0085","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia ankara as a vaccine against smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.vaccine.2024.05.017_b0090","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.vaccine.2013.04.050","article-title":"Safety and immunogenicity of IMVAMUNE\u00ae smallpox vaccine using different strategies for a post event scenario","volume":"31","author":"Frey","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.05.017_b0095","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2024.05.017_b0100","doi-asserted-by":"crossref","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","article-title":"Estimated effectiveness of JYNNEOS vaccine in preventing Mpox: a multijurisdictional case-control study - United States, August 19, 2022-March 31, 2023","volume":"72","author":"Dalton","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.05.017_b0105","doi-asserted-by":"crossref","unstructured":"Payne AB, Ray LC, Cole MM, et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(49): 1560-4.","DOI":"10.15585\/mmwr.mm7149a5"},{"issue":"11","key":"10.1016\/j.vaccine.2024.05.017_b0110","doi-asserted-by":"crossref","first-page":"ofad528","DOI":"10.1093\/ofid\/ofad528","article-title":"Effectiveness of the modified vaccinia ankara vaccine against Mpox in men who have sex with men: a retrospective cohort analysis, Seattle, Washington","volume":"10","author":"Ramchandani","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2024.05.017_b0115","unstructured":"Centers for Disease Control and Prevention. 2022-2023 Outbreak Cases and Data. <https:\/\/www.cdc.gov\/poxvirus\/mpox\/response\/2022\/index.html> [accessed 2024]."},{"key":"10.1016\/j.vaccine.2024.05.017_b0120","unstructured":"DC Health. DC Health Confirms First Orthopoxvirus and potential Monkeypox Case in the District. <https:\/\/dchealth.dc.gov\/release\/dc-health-confirms-first-orthopoxvirus-and-potential-monkey-pox-case-district> [accessed December 1]."},{"issue":"2","key":"10.1016\/j.vaccine.2024.05.017_b0125","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/cid\/ciad145","article-title":"Evidence of Mpox virus infection among persons without characteristic lesions or rash presenting for first dose of JYNNEOS vaccine-district of columbia, August 2022","volume":"77","author":"Ogale","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2024.05.017_b0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"7","key":"10.1016\/j.vaccine.2024.05.017_b0135","first-page":"867","article-title":"characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak","volume":"12","author":"Karem","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2024.05.017_b0140","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc2306239","article-title":"Antibody titers against mpox virus after vaccination","volume":"389","author":"Kottkamp","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.05.017_b0145","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/infdis\/jiac455","article-title":"One- and two-dose vaccinations with modified vaccinia ankara-bavarian nordic induce durable B-cell memory responses comparable to replicating smallpox vaccines","volume":"227","author":"Ilchmann","year":"2023","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2024.05.017_b0150","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","article-title":"Cutting edge: long-term B cell memory in humans after smallpox vaccination","volume":"171","author":"Crotty","year":"2003","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.05.017_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/v13010043","article-title":"There, and everywhere: the wide host range and geographic distribution of zoonotic orthopoxviruses","volume":"13","author":"Silva","year":"2020","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2024.05.017_b0160","doi-asserted-by":"crossref","first-page":"e0157335","DOI":"10.1371\/journal.pone.0157335","article-title":"A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of modified vaccinia ankara smallpox vaccine (MVA-BN\u00ae) in 56\u201380-year-old subjects","volume":"11","author":"Greenberg","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2024.05.017_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/v14091960","article-title":"Vaccinia-virus-based vaccines are expected to elicit highly cross-reactive immunity to the 2022 Monkeypox Virus","volume":"14","author":"Ahmed","year":"2022","journal-title":"viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2024.05.017_b0170","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","article-title":"Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals","volume":"29","author":"Zaeck","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2024.05.017_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2023.05.001","article-title":"Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals","volume":"31","author":"Hubert","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"11","key":"10.1016\/j.vaccine.2024.05.017_b0180","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","article-title":"Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study","volume":"23","author":"Cohn","year":"2023","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24005632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24005632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T10:22:53Z","timestamp":1728642173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24005632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0264410X24005632"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}